Who We Are
The GID Story
Receive Our Newsletter
The GID Story
Who We Are
Terms and Conditions of Use
Page Not Found
Be Right Back
View all articles
Tulane University School of Medicine announces FDA-approved pivotal / Phase III clinical trial for patients with knee osteoarthritis
Aerospace to cellular medicine: How GID BIO’s CEO used his expansive engineering background to help design a scalable device for cell therapy, on track to potentially become the first FDA-approved therapy for treating knee osteoarthritis
GID BIO addresses a growing need for cost-effective U.S. osteoarthritis treatments
American Journal of Sports Medicine publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain
An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France
Physicians: advancing the future of evidence-based cellular medicine could increase quality of life for 14 million US adults suffering from knee osteoarthritis
Leaders come together for the first time to advance the field of cellular medicine and its treatment of pain and function associated with knee osteoarthritis
Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults
GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy
Precision medicine could improve treatment for 14 million U.S. adults with knee osteoarthritis
American Journal of Sports Medicine to publish results of an FDA-approved clinical trial
Device and point-of-care therapy intended to treat pain and function could soon help knee osteoarthritis patients
FDA-approved trial for cellular implant therapy could mean a major development in the treatment of pain associated with knee osteoarthritis
6 Orthobiologic Companies Move Clinical Trials Forward
GID BIO aims to close a healthcare gap with the launch of a cost-effective treatment for those suffering from osteoarthritis
Beyond knee osteoarthritis: GID explores cellular medicine to potentially treat dermal, organ and more musculoskeletal diseases
GID BIO’s results in FDA-approved, multi-site, randomized, placebo-controlled Phase IIb clinical trial support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee
GID BIO, a cellular medicine company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system
Initial safety and feasibility of cellular medicine therapy
In the news
GID BIO seeks up to USD 25m to support cellular medicine platform, CEO says
GID BIO Completes Trial of Stromal Cells to Treat Knee OA
Morgan St. John
PATRICK MAXWELL, M.D.
Adam Katz, M.D.
Ramon Llull, M.D. and Ph.D.
William Futrell, M.D.
William Cimino, Ph.D.
Training & Education